Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Completed · Phase 1
Conditions studied: Relapsed/Refractory Mantle Cell Lymphoma
In brief
This Phase I/II trial studies the safety and effectiveness of lenalidomide with or without idelalisib. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lenalidomide is more effective with or without idelalisib in treating mantle cell lymphoma.
Key facts
- Study ID
- NCT01838434
- Run by
- Alliance for Clinical Trials in Oncology
- People needed
- 106
- Starts
- 2013-10-17
- Expected to finish
- 2017-05-01
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago — Chicago, Illinois, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Ohio State University Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.